Bio-business in brief: the debate over biosimilars

Biogenerics, or biosimilars, are a contentious subject. Some of the issues in this debate are outlined here such as should they be allowed onto the market or should they not. The biosimilars that have already been approved in India and in Europe are also listed.

Saved in:
Bibliographic Details
Published in:Current science (Bangalore) 2010-06, Vol.98 (12), p.1575-1578
Main Author: Saberwal, Gayatri
Format: Article
Language:English
Subjects:
Biology
Business innovation
Business structures
Drug regulation
GENERAL ARTICLES
Government regulation
Heparin
Manufacturing processes
Medical treatment
Molecules
Pharmaceutical industry
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Biogenerics, or biosimilars, are a contentious subject. Some of the issues in this debate are outlined here such as should they be allowed onto the market or should they not. The biosimilars that have already been approved in India and in Europe are also listed.
ISSN:0011-3891